ObesityWeek®? 2024 | Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese Adults

Gan & Lee Pharmaceuticals Denmark Finland Germany Netherlands Sweden United Kingdom China New York New Jersey

Obese or overweight participants receiving bi-weekly doses of 12 mg, 18 mg, 24 mg, 48 mg, and once-weekly dose of 24 mg GZR18 for 30 weeks achieved mean percent changes in body weight from baseline of -11.15%, -13.22%, -14.25%, -17.29%, and -17.78%, respectively, with the placebo group at -0.99%; and at 30 weeks, participants' body weight continued to decrease.The clinical efficacy and safety of bi-weekly 48 mg and once-weekly 24 mg GZR18 injections were comparable, with no significant difference in mean percent change in body weight from baseline between the two groups (one-sided test, P > 0.025).GZR18 injections were safe and well tolerated, with the most commonly reported adverse events being gastrointestinal reactions, comparable to similar drugs.View original content:https://www.prnewswire.co.uk/news-releases/obesityweek-2024--gan--lee-pharmaceuticals-orally-presents-phase-2b-clinical-data-for-gzr18-injection-in-chinese-overweight-and-obese-adults-302301121.html